Introduction
The limb skeleton is largely comprised of endochondral bones, which initially form as cartilage templates and are ultimately replaced by bone. Cartilage formation of the limb skeleton begins with the migration of mesenchymal progenitor cells (MPCs) from the lateral plate mesoderm into the developing limb field. MPCs undergo rapid proliferation expanding the limb-bud, followed by the formation of mesenchymal condensations that will give rise to individual cartilage elements via chondrogenesis. This process, which generates mature chondrocytes or cartilage cells from MPCs via differentiation, is primarily driven by the expression and activity of the transcription factor SOX9. SOX9 induces and maintains the expression of numerous cartilage-related genes including collagen type II (Col2a1) and aggrecan (Acan) as well as drives growth of cartilage elements (Akiyama et al., 2002; Horton, 2003) . As cartilage rudiments continue to develop, chondrocytes near the center of the elements undergo phenotypic and molecular changes known as pre-hypertrophy and hypertrophy, which are regulated and marked by the sequential activation of genes including indian hedgehog (Ihh), runt related transcription factor 2 (Runx2), collagen type X (Col10a1), matrix metalloproteinase 13 (Mmp13), and the concomitant down-regulation of Sox9. The cartilage matrix is ultimately removed via the activity of terminally hypertrophic chondrocytes, which secrete MMP13 to catabolize or degrade the cartilage matrix creating a scaffold for newly formed osteoblasts to lay down bone matrix (Zuscik et al., 2008) .
The Notch signaling pathway is a known regulator of chondrogenesis, chondrocyte hypertrophy, cartilage matrix catabolism, and osteoblastogenesis (Dong et al., 2010; Zanotti and Canalis, 2010; Kohn et al., 2012; Liu et al., 2015) . Activation of the Notch pathway Notch1 and 2, and Rbpjk) within MPCs using the Prx1Cre or within cartilage progenitor cells using a Col2Cre transgene delayed the onset and progression of chondrocyte hypertrophy and cartilage matrix catabolism (Hilton et al., 2008; Kohn et al., 2012) , while activation of NICD in committed chondrocytes both in vivo and in vitro promoted chondrocyte hypertrophy and cartilage matrix catabolism (Mead and Yutzey, 2009; Kohn et al., 2012) . Recently, we also demonstrated that several of the Notch-mediated effects on cartilage development occur in an RBPJk-dependent manner (Dong et al., 2010) and are likely the consequence of an indirect transcriptional regulation of Sox9 (Kohn, 2015) . While the importance of Notch signaling in cartilage development has been well documented, the precise molecular mechanism(s) by which Notch regulates these distinct processes remain unclear or unknown.
Hairy and Enhancer of Split (HES) and Hairy and Enhancer of Split Related (HEY)
proteins are bHLH transcription factors, of which several are molecular - (Fig. 1A) . The hypertrophic chondrocyte markers, Col10a1 and Mmp13, were most highly expressed at day 28 indicating that the majority of cells had reached hypertrophy (Fig. 1A) . We next analyzed the expression of Hes1, Hes3, Hes5, Hes7, and Hey1. Hes1 reached peak expression at day 21 and then decreased at day 28 (Fig. 1A) . Hes5 was highly expressed at day 7 followed by a reduction in expression at days 14 and 21, and then was
Journal of Cell Science • Advance article elevated again at day 28 (Fig. 1A) . When comparing the expression of Hes5 to Sox9, there appears to be an inverse relationship between the two genes such that if one is highly expressed the other is decreased in expression. Hey1 expression was highest at day 28 and lower at earlier stages of chondrogeneis, suggesting a potential role in chondrocyte hypertrophy (Fig. 1A) . Other Hes genes were also analyzed but largely could not be detected during chondrogenesis and chondrocyte hypertrophy of ATDC5 cells in culture.
To determine whether HES factors demonstrated similar expression profiles during chondrogenesis in vivo, we isolated RNA and protein from wild-type (WT) embryonic day 10.5 and 11.5 (E10.5 and E11.5) limb-buds. Using qPCR, we observed a similar trend between Hes1 and Sox9 as well as between Hes5 and Sox9; that is, increased Hes1 expression was observed as Sox9 increases from E10.5-E11.5, while Hes5 expression decreases as Sox9 increases from E10.5-E11.5 (Fig. 1B) . We then analyzed HES1 and HES5 protein expression in E10.5 and E11.5 limb-buds using Western blot analysis. Similar to the qPCR data, we again observed increased HES1 as SOX9 increases from E10.5-E11.5, while HES5 decreased as SOX9 increased from E10.5-E11.5 (Fig. 1C) (Fig. S1Aa-b) or Col2a1 ( Fig. S1Ac-d Hes5 by analyzing their expression via qPCR on RNA isolated from E10.5 Hes1,5 LOF and WT limb-buds ( Fig. 2A) . Using SOX9 immunohistochemistry (IHC) on E10.5 Hes1,5 LOF and WT control limb-bud sections, we observed a subsequent increase in the expression of SOX9 in Hes1,5 LOF limb-buds as compared to WT (Fig. 2Ba-b ). These data demonstrate an early acceleration in MPC differentiation and chondrogenesis. We next analyzed E11.5
Hes1,5 LOF and WT embryos. Similar to E10.5 limb-bud sections, we performed SOX9 IHC and observed increased SOX9 in the Hes1,5 LOF limb-buds as compared to WT ( Fig. 2Bc-d ). We also performed qPCR on RNA isolated from E11.5 Hes1,5 LOF and control limbbuds. At E11.5, we observed a significant increase in both Sox9 and Col2a1 expression in Hes1,5 LOF limb-buds ( Fig. 2A) , further suggesting an acceleration in MPC differentiation and chondrogenesis in the absence of Hes1 and Hes5. Lastly, we analyzed expression of COL2A1 and ACAN protein and RNA at E12.5 in WT and Hes1,5 LOF limb-buds. Alcian
Blue/Hematoxylin/Orange G (ABH/OG) staining, which stains cartilage matrix blue, showed that Hes1,5 LOF mutant limbs displayed enhanced or accelerated cartilage formation in the radius and ulna, with more clearly defined joint formation in regions of the developing
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humerus and ulna when compared to WT sections ( Fig. 2Ca-b) . Protein analysis using IHC demonstrated altered COL2A1 expression associated with advanced secondary chondrogenesis and joint formation ( Fig. 2Cc-f ) and an increase in ACAN expression ( Fig. 2Cg-j) in E12.5 Hes1,5 LOF forelimbs as compared to WT controls. Further analysis at this time point revealed a change in cellular morphology. As chondrocytes mature prior to hypertrophy, they begin to flatten (Zuscik et al., 2008) . In E12.5 Hes1,5 LOF limb buds, we observed more flattened cells compared to WT controls ( Fig. 2Ci-j) . This indicates that the cells in the Hes1,5 LOF limb-bud are beginning to form the columnar zone of proliferating chondrocytes, which occurs just prior to hypertrophy. This is not observed as clearly in the WT control sections. Lastly, we analyzed RNA from E12.5 wild-type and Hes1,5 LOF mutant limb-buds using qPCR. Gene expression analysis showed that the loss of Hes1 and
Hes5 resulted in a significant increase in Col2a1 and Acan expression ( Fig. 2A) . We did not observe any change in Sox9 at this time point, which is likely due to the fact that as chondrocytes begin to mature, Sox9 levels decrease ( Fig. 2A) .
Collectively, these data demonstrate that Hes1 and Hes5 are necessary for appropriate MPC differentiation and chondrogenesis.
HES1 over-expression in MPCs delays chondrogenesis and induces MPC proliferation.
To determine whether Hes1 is sufficient to suppress chondrogenesis, we analyzed (Kobayashi and Kageyama, 2010) . We first analyzed Hes1 and chondrogenic gene expression from E12.5 Rosa-Hes1 and WT limbbuds using qPCR. We observed a significant over-expression of Hes1 and a significant decrease in both Col2a1 and Acan expression in Rosa-Hes1 limb-buds as compared to WT (Fig. 3A) . Interestingly, Sox9, Sox5, and Sox6 gene expression was largely unchanged in Rosa-Hes1 limb-buds as compared to WT (Fig. 3A) . Histological analyses of E12. forelimbs compared to WT controls (Fig. 3Cc) . We also isolated protein from E11.5 RosaHes1 and WT limb-buds to perform Western blot analysis of the proliferative marker, CyclinD1 (CYCD1). Rosa-Hes1 limb-buds demonstrated increased CYCD1 protein as compared to WT controls further validating the observed increase in proliferation (Fig. 3D) .
Collectively, these data demonstrate that Hes1 is sufficient to delay chondrogenesis by suppressing Col2a1 and Acan gene expression, and is also capable of expanding the MPC population during early limb development.
HES, but not HEY, factors regulate early chondrocyte hypertrophy potentially via suppression of SOX9.
We have shown previously that RBPjκ-dependent Notch signaling is an important regulator of the onset and progression of chondrocyte hypertrophy (Hilton et al., 2008; Kohn et al., 2012; Kohn, 2015) . To determine whether HES1 regulates the onset and progression of chondrocyte hypertrophy, we first analyzed Hes1 LOF and WT embryos at E14.5. Hes1 LOF forelimbs were analyzed using histological staining and in situ hybridization for markers of chondrocyte maturation. ABH/OG staining of E14.5 Hes1 LOF mutant forelimbs exhibit a mild and largely inconsistent decrease in the length of the hypertrophic zone ( Fig. S1Ca-b) , which is also observed via reduced domains of Col10a1 (Fig. S1Cc-d) and
S1Ce-f) expression as compared to WT controls. Collectively, these data suggest that Hes1 may play a limited role in regulating the onset of chondrocyte hypertrophy at E14.5 or that compensation by other HES factors, such as HES5, may be blunting the effect of Hes1 LOF alone.
To determine whether Hes5 compensatory expression may also be affecting chondrocyte hypertrophy in Hes1 LOF mutants, we generated and analyzed E13.5 Hes1,5
LOF mutant and WT embryos via histological approaches. Hematoxylin and Eosin (H&E)
staining of humerus sections demonstrate that Hes1,5 LOF mutants have a smaller hypertrophic zone compared to WT controls (Fig. 4Aa-b) . In situ hybridization for the hypertrophic chondrocyte marker, Col10a1, indicated a clear lack of expression in E13.5
Hes1,5 LOF mutant humerus sections compared to WT (Fig. 4Ac-d Fig. 4Ae-f) . These data suggest that the delay in the onset of chondrocyte hypertrophy may be due to the maintenance of SOX9 expression.
To determine whether the loss of Hes1 and Hes5 results in a continuous delay in chondrocyte hypertrophy, we analyzed E14.5 Hes1,5 LOF mutant and WT limb skeletons.
H&E staining revealed a decrease in the length of the hypertrophic zone in E14.5 Hes1,5
LOF humerus sections as compared to WT (Fig. 4Ba-b) . Furthermore, Hes1,5 LOF forelimbs exhibit a decrease in the Col10a1 (Fig. 4c-d) and Mmp13 (Fig. 4Be-f ) expression domains at E14.5. To determine if this continued delay in hypertrophy is due to altered SOX9 expression, we used IHC analysis. Similar to the Hes1,5 LOF data at E13.5, we observed maintenance of SOX9 expression deeper into the hypertrophic zone of E14.5 mutant forelimbs ( Fig. 4Bg-j) . To determine if this decrease size of the hypertrophic zone was statistically significant, we measured the length of the hypertrophic zones and normalized to total lengths of the cartilage elements for WT and Hes1,5 LOF mutants. Quantitative analysis showed a significant decrease in the length of the hypertrophic zone in the Hes1,5 LOF mutant forelimbs compared to WT (Fig. 4C) . To ensure this delay in hypertrophy was not due to changes in proliferation, we utilized BrdU IHC analysis, and did not observe any change in the percentage BrdU+ cells in Hes1,5 LOF humerus sections as compared to WT (Fig. S2A-B) . Combined, these data demonstrate that HES1 and HES5 control the pace of chondrocyte hypertrophy, potentially via SOX9 regulation.
We next analyzed terminal chondrocyte hypertrophy and cartilage matrix catabolism using E18.5 Hes1,5 LOF and WT humerus sections. Interestingly, no delay in terminal chondrocyte hypertrophy or cartilage matrix turnover was observed between Hes1,5 LOF and WT cartilage elements, as indicated by similar zones of hypertrophy in ABH/OG stained sections (Fig. S2Ca-b ) and a lack of any change in MMP13 expression (Fig. S2Cc-d) . This was consistent with data demonstrating that genetic removal of Hes1 alone within MPCs caused no obvious defects in terminal chondrocyte hypertrophy and cartilage matrix turnover, as indicated by similar zones of hypertrophy in E18.5 Hes1 LOF and WT H&E stained sections (Fig. S2Da-b) and similar expression domains of Ihh (Fig. S2Dc-d 
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S2De-f), and Mmp13 (Fig. S2Dg-h) . Surprisingly, neither Hes1 LOF or Hes1,5 LOF mutants appeared to exhibit an expanded hypertrophic zone at E18.5, which was observed previously in several Notch LOF mutant mice and is indicative of a continuous delay in terminal chondrocyte hypertrophy and cartilage matrix catabolism (Hilton et al., 2008; Mead and Yutzey, 2009; Kohn et al., 2012; Kohn, 2015) . Based on these data combined with the observation that HEY factor expression increases in maturing and hypertrophic chondrocytes (Fig. 1A) , we obtained and analyzed E14.5 and E18.5 Hey1 -/-; HeyL -/-double mutant (Hey1,HeyL LOF) and control embryos for defects in the onset and progression of chondrocyte hypertrophy and cartilage matrix catabolism. H&E staining (Fig. S3Aa-b , Bab), and in situ hybridization for Ihh (Fig. S3Ac-d, Bc-d) , Col10a1 (Fig. S3Ae-f , Be-f), and Mmp13 ( Fig. S3Ag-h , Bg-h) on tibia sections at E14.5 and E18.5 demonstrate no obvious changes in the hypertrophic zones between Hey1,HeyL LOF and control cartilage elements.
Collectively, these data demonstrate that HES factors (particularly HES5) primarily control the onset of chondrocyte hypertrophy during cartilage maturation, potentially via SOX9 regulation, while neither the HES or HEY factors appear to control terminal chondrocyte hypertrophy or cartilage matrix catabolism.
HES1 over-expression in MPCs delays chondrocyte hypertrophy and inhibits skeletal growth.
To determine whether Hes1 over-expression in MPCs affects chondrocyte proliferation and hypertrophy during cartilage development and maturation, we first examined Rosa-Hes1 and WT E14.5 skeletal preparations via alcian blue staining. Rosa-Hes1 cartilage rudiments were shorter, and the limbs as a whole, were smaller than WT controls (Fig. 5Aa-d) . In the most severely affected Rosa-Hes1 forelimbs (Fig. 5Ab) and hindlimbs (Fig. 5Ad) , we observed a hypoplastic or missing radius and/or fibula (black arrows). Distal cartilage rudiments appeared to be more severely affected as compared to proximal elements, and hindlimbs were more affected than forelimbs (Fig. 5Aa-d) . Analysis of alcian blue stained hindlimbs shows the formation of a defined hypertrophic zone in WT cartilage rudiments (Fig. 5Ac) (red asterisks), although these were largely absent in severely affected Rosa-Hes1 mutants at this stage (Fig. 5Ad) . ABH/OG staining of E14.5 humerus sections (the least affected proximal element) (Fig. 5Ba-b) demonstrated that Rosa-Hes1 mutants exhibited only a mild delay in chondrocyte hypertrophy as compared to WT controls, with only minor changes in Col10a1 (Fig. 5Bc-d) and Mmp13 (Fig. 5Be-f ) expression within the hypertrophic zone.
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To assess whether changes in chondrocyte proliferation could contribute to the RosaHes1 skeletal phenotype, we performed BrdU staining on E14.5 Rosa-Hes1 and WT humerus sections (Fig. 5Ca-b) . Consistent with the reduced size observed in most elements of RosaHes1 mutants, we observed a decrease in the percentage of BrdU positive chondrocytes (Fig.   5Cc ). We next analyzed overall growth changes of skeletal elements at E18.5 using RosaHes1 and WT forelimb (FL) and hindlimb (HL) skeletal preparations (Fig.   5Da ,Db,Dd,De,Dg,Dh,Dj,Dk). Analyses indicated that the total lengths of these bones are significantly shorter in Rosa-Hes1 mutants as compared to WT controls, with the most prominent effects occurring on distal elements (Fig. 5Dc ,Df,Di,Dl). Interestingly, Rosa-Hes1 mutant mice survive to adulthood and present with various skeletal anomalies including alterations to skeletal patterning, bone ridge or tuberosity development, and digit number.
These phenotypes are the likely result of the early and broad effects of the Prx1Cre transgene controlling Hes1 over-expression in skeletal progenitors. The precise cellular and molecular mechanisms underlying each of these peripheral phenotypes will be explored and described elsewhere. These data presented here suggest that Hes1 over-expression in MPCs can delay chondrocyte hypertrophy and reduce chondrocyte proliferation, although these effects may be secondary to the delay in chondrogenesis described earlier.
HES5 directly regulates Sox9 expression.
Since chondrogenic differentiation from MPCs and early chondrocyte hypertrophy are coordinated by the expression and activity of SOX9, we next examined whether HES factors could transcriptionally regulate Sox9 expression. Earlier we demonstrated that Hes1 overexpression in MPCs in vivo is sufficient to repress Col2a1 and Acan expression without affecting Sox9 expression (Fig. 3A) . To determine whether HES5 is capable of regulating
Sox9 expression, we first transfected ATDC5 chondrogenic cells with either Flag (control) or
Hes5 over-expression constructs. After seven days in chondrogenic differentiation media, RNA was isolated for qPCR analysis from each group. Hes5 over-expression resulted in a notable reduction of Sox9, Sox5, and Sox6, as well as chondrogenic genes such as Col2a1 and
Acan, although to a lesser degree at this time-point (Fig. 6A) . These data suggest HES5 is sufficient to down-regulate or delay chondrogenesis in vitro and may directly regulate Sox9 expression.
-dependent Notch regulation of Sox9, however, the exact mechanism remains unknown or controversial (Mead and Yutzey, 2009; Dong et al., 2010; Kohn et al., 2012; Chen et al., 2013; Kohn, 2015) . Recent data has
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suggested that the Notch-mediated transcriptional regulation of Sox9 occurs indirectly via secondary effectors (Kohn, 2015) . Therefore, we first used a bioinformatics approach to search the Sox9 promoter for HES binding sites, N-box/E-box sequences (Fig. S4A) . We identified two N-box/E-box sequences within the first kilobase of the Sox9 promoter that were 100% conserved between the mouse and human genomes (Fig. S4C) . To determine whether HES5 directly binds this region of the Sox9 promoter in MPCs and chondrogenic cells in vivo, we utilized chromatin immunoprecipitation (ChIP) assays on DNA isolated from WT E10.5 and E11.5 limb-buds. As previously indicated, Hes5 and Sox9 expression demonstrated an inverse relationship in E10.5 and E11.5 limb-buds (Fig. 1Ba-b ). Primers were designed to amplify the region of the Sox9 promoter containing the N-box/E-box (Fig.
S4B [red arrows]) and a negative control region approximately 19kb upstream of N-box/Ebox sequences (Fig. S4B [green arrows])
. ChIP analysis at E11.5 using a HES5 antibody revealed amplification of DNA when using primers flanking the N-box/E-box sequence (Primer 2; P2)(Lane 8), and no amplification when using primers targeting an upstream region of the Sox9 promoter (Primer 1; P1)(Lane 7) (Fig. 6Ba) . Interestingly, no amplification of either primer set was observed when ChIP analyses were performed with a HES1 antibody (Lanes 5 and 6) (Fig. 6Ba) , indicating specificity of binding to the N-box/Ebox site for HES5. We also observed positive control amplification from the sheared genomic DNA (Lanes 1 and 2) when using P1 and P2 primers, while IgG pull downs showed no amplification (Lanes 3 and 4) (Fig. 6Ba) . By performing qPCR on DNA pulled down during ChIP assays from E10.5 and E11.5 limb-buds, we were able to determine that the occupancy of HES5 on the Sox9 promoter region was greater at E10.5 than E11.5 (Fig. 6Bb) . These data -dependent Notch regulation of Sox9 works in part through direct HES5 transcriptional activity.
Finally, we utilized a 1.0kb Sox9 promoter driven luciferase construct that includes the N-box/E-box sequence to demonstrate the direct transcriptional regulation of Sox9 by HES5. When this construct was co-transfected with Flag, NICD1, and Hes5 expression vectors, we observed a significant and similar level of luciferase activity suppression between NICD1 and Hes5 transfected groups when compared to the Flag transfected control (Fig.   6Ca ). However, when we co-transfected a 1.0kb Sox9 promoter driven luciferase construct containing a mutated N-box sequence with Flag or Hes5 expression vectors, we observed no change in luciferase activity (Fig. 6Cb) . ) failed to show any defects in cartilage development (Karlsson et al., 2010) . Importantly, this study only analyzed embryos at E16.5 and later time-points during endochondral bone development, thereby potentially missing the earlier defects we have expression as well as other cartilage catabolizing enzymes, while prolonged over-expression of Hes1 was also shown to induce some of these same catabolic genes in vitro (Sugita et al., 2015) . Therefore, it is possible that HES, and potentially HEY, factor regulation of catabolic gene expression may only be evident in pathological or injury/inflammation settings and that during development Notch signaling regulates terminal chondrocyte hypertrophy and cartilage matrix catabolism via alternative mechanisms. Alternatively, numerous HES/HEY factors may contribute to the regulation of this aspect of Notch function in cartilage, and therefore would require the elimination of nearly all Hes/Hey genes simultaneously to uncover their requisite role in regulating cartilage catabolism during normal development.
While the importance of Notch signaling in skeletal development, injury, and disease has recently come to light, we are just beginning to learn about the underlying Notchmediated molecular mechanisms that control these distinct events. Identifying these molecular players and their function may not only provide us with additional important molecules to consider when examining skeletal disorders, but may also generate additional drug targets for the treatment of these conditions or ailments. For example, Hajdu Cheney Syndrome (HCS) is a rare, heritable multi-organ connective tissue disorder that presents with significant skeletal features such as skull deformities, short stature, joint laxity, and a severe reduction in bone mass or osteoporosis and is caused by heterozygous mutations in the NOTCH2 receptor (Majewski et al., 2011; Simpson et al., 2011) . While it has been recently discovered that these mutations lead to Notch GOF within connective tissue cells (Majewski et al., 2011; Simpson et al., 2011) , the precise downstream effectors that drive the pathology are unknown. Adams-Oliver Syndrome (AOS) is another rare heritable disorder characterized by skin and limb defects including hypoplastic or shortened digits, absence of bones in hands or the feet, as well as, partial or complete absence of the lower legs (tibia/fibula/digits). AOS is an autosomal dominant disorder caused by mutations in RBPjk and/or NOTCH1 genes resulting in Notch LOF, although no additional molecular mechanisms underlying this disease is known (Hassed et al., 2012; Stittrich et al., 2014) . Notch signaling defects, either GOF or LOF, have also been implicated in osteoarthritis (Mahjoub et al., 2012; Hosaka et al., 2013; Mirando et al., 2013; Sassi et al., 2014; Liu et al., 2015) , rheumatoid arthritis (Nakazawa et al., 2001; Park et al., 2015) , osteoporosis (Engin et al., 2008; Hilton et al., 2008; Majewski et al., 2011; Simpson et al., 2011) , and a predisposition to pathologic fractures (Kung et al., 2010) . Studies like the one presented here furthers our understanding of the molecular players and events in which Notch signaling may control normal skeletal development, as well as, contribute to the pathology of certain skeletal diseases and injury processes.
Materials and Methods

Mouse Strains
The Prx1Cre mouse line was previously described (Logan et al., 2002) . The Hes1 f/f , and
, and Rosa-Hes f/f strains were a generous gift from Dr. Ryoichiro Kageyama (Institute for Virus Research, Kyoto University) and were described previously (Cau et al., 2000; Hirata et al., 2001; Imayoshi et al., 2008; Tateya et al., 2011 ) (Kobayashi et al., 2009 ).
Hey1 -/-; HeyL -/-mutant and control embryos were provided by Dr. Manfred Gessler (Biozentrum Universitat Wurzburg) and have been previously described (Fischer et al., 2007) . All animal work has been approved by both the Duke University and University of Rochester Institutional Animal Care and Use Committees (IACUC).
Real-time RT-PCR
Isolation of RNA from limb-bud tissues and ATDC5 cultures were performed as previously described (Kohn, 2015) . Real-time RT-PCR was used to analyze relative gene expression using the Bio-Rad CFX Connect Real-Time System. Gene expression was normalized to -actin before being normalized to control samples. Mouse specific primers for Sox9, Sox5,
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Sox6, Col2a1, Acan, Hes1, Hes3, Hes5, Hes7 , and Hey1 were designed as described previously (Dong et al., 2010) . Primer sequences are available upon request. Gene expression analyses from limb-buds are from representative experiments of at least three biological replicates from pooled genotypes with statistical analyses performed on technical replicates of an individual experiment.
Tissue Analysis
Embryos were harvested at E10.0-E18.5 in cold 1X phosphate buffered saline (PBS), fixed in 10% neutral buffered formalin (NBF), and then processed. Embryos >E12.5 were treated overnight with 14% ethylenediaminetetraacetic acid (EDTA). After processing, tissues were paraffin embedded. For embryos E10.0-E11.5, the whole embryo was embedded; limbs from E12.5-E14.5 embryos were dissected off of whole embryo before embedding. Tissue was then sectioned at 4μm and 5μm for E10.0-E12.5 and E13. (Thermo Scientific), SOX9 (Santa Cruz Biotechnology), and MMP13 (Thermo Scientific).
Standard heat induced and sodium citrate antigen retrievals were performed for the previously listed antibodies, while no antigen retrieval was performed for SOX9 IHC.
Relative quantification of some IHC staining intensities were calculated using the IHC image analysis toolbox developed in ImageJ. Briefly, DAB stained pixels were first "trained" by the software to build a statistical positive stain detector. By selecting a region of interest in the image, pixels of the original image were displayed with original color values, while all other pixels were set to 255 as background and thus filtered out during the color detection process.
Finally, only DAB stained pixels were quantified and compared between groups. BrdU IHC was performed as previously described (Dong et al., 2010) . For in situ hybridization, embryos were prepared, fixed, processed, and sectioned as described previously (Hilton et al., 2005; Hilton et al., 2007; Hilton et al., 2008; Dong et al., 2010) . Dig-labeled whole-mount in situ hybridizations were performed as described (Rutkowsky et al., 2014) . Skeletal staining was performed using the protocol as previously described (Dong et al., 2010) .
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Chromatin Immunoprecipitation assay (ChIP)
The ChIP assay was performed using the MAGnify Chromatin Immunoprecipitation System (Invitrogen) on E10.5 and E11.5 limb-buds. Limb-buds were homogenized in cold PBS using a 24g syringe and immediately frozen using liquid nitrogen. Sonication was performed using a Covaris S2 sonicator according to manufacturers instructions in order to shear chromatin to the lengths of 100-300 base pairs. The protocol was optimized for the use of 6-10 limb-buds.
Antibodies for HES1 and HES5 (Santa Cruz Biotechnology) were used at a concentration of qPCR with primers specifically designed to amplify the region of interest within the Sox9 gene promoter.
ATDC5 Cell Analysis
ATDC5 cells (RIKEN BRC, Japan) were grown in a 12-well plate with DMEM/F12 1:1 (Invitrogen) supplemented with 5% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Once cells were 70-80% confluent, they were treated with ITS media: standard DMEM/F12 media ml), and selenous acid (5ng/ml)] (BD Biosciences). Treatment with ITS supplement has been previously reported to induce chondrocyte differentiation (Watanabe et al., 2001 ). Cells were incubated for 4 days with ITS media before transfection with Flag, NICD1, and/or Hes5 over expression plasmids. Transfection was achieved using FuGENE HD (Promega) with 500ng of each construct. Cells were cultured for 7 days changing media every 48 hours.
Luciferase assays were also performed in ATDC5 cells using a 1kb Sox9 luciferase construct and a N-box mutant 1kb Sox9 luciferase construct using the same protocol and reagents as described previously (Kohn, 2015) . Western and luciferase analyses are representative experiments of at least three biological replicates with statistical analyses performed on technical replicates of an individual experiment. Real-time RT-PCR statistical analyses were performed on the means of three biological replicates.
Western Blot
Total proteins were isolated from WT and mutant limb-buds. Limb-buds were dissociated in a standard lysis buffer and protease inhibitor solutions. Approximately, 10g of protein was separated using NuPAGE Novex 4-12% Bis-Tris pre-cast gels (Invitrogen) and the fractionated protein lysates were transferred onto a nitrocellulose membrane using the iBlot 
Statistical analysis
Statistical analyses were performed using two-tailed Student's t-test and one way ANOVA; a P value < 0.05 was considered significant. 
